I-SARS-CoV-2 (COVID19) iyagquba kwihlabathi jikelele, kwaye ugonyo luvunywa njengeyona ndlela inoqoqosho nesebenzayo yokulawula ubhubhane wentsholongwane. Uvandlakanyo lwesitofu sogonyo lwesintu ikakhulu lusebenzisa iindlela zokubhaqa ii-antibody ukuze zivavanye ukusebenza kogonyo ngokusebenzisa imifuniselo yokungathathi hlangothi;
Iindlela zesiNtu zidla ixesha kwaye zisebenza kancinci, zihlala zithatha iintsuku ezi-2 ukuya kwezi-4 ukugqiba uphononongo, kwaye ngenxa yokuba uninzi lwazo zisebenzisa iintsholongwane eziphilayo, Kufuneka kuqhutywe kwinqanaba le-biosafety 3 okanye ngaphezulu kwilabhoratri, elixesha- iyatya kwaye ibulaleka, kwaye izisa ukuphazamiseka okukhulukuvavanyo lokwandiswa nokuhlanganiswa. Ke ngoko, kukho imfuno engxamisekileyo yendlela elula nekhawulezayo eyenye ekulungeleyo ukuphononongwa kwezilwa-buhlungu ezikhuselayo kuluntu olukhulu.
I-Aehealth COVID19 Neutralization Antibody Rapid Test Kits isetyenziswa ekubhaqweni kwezilwa-buhlungu ze-COVID19 zokungathathi hlangothi kwiserum yomntu, iplasma okanye igazi lilonke. Ingasetyenziselwa ukukhangela okukhawulezayo, okubukhali kakhulu kwi-vitro. esetyenziswa ekliniki kuvavanyo oluncedisayo lwesiphumo sesitofu sokugonya se-COVID19 kunye novavanyo lwe-anti-neutralization antibodies kwizigulana ezibuyiselweyo emva kosulelo.
Ukusebenza lula
- Akukho mfuneko yokuba iingcali ziqeqeshwe
- Iyahambelana nohlobo lwemizekelo emininzi: iSerum/Plasma/Igazi elipheleleyo/umnwe wegazi elipheleleyo.
Iluncedo
- Akukho sixhobo sifunekayo
Esebenzayo
- Uvavanyo: 15-20 imizuzu;
Izithinteli-mpilo ezingathathi hlangothi zilunqanda ngokufanelekileyo usulelo ngokuthintela unxibelelwano phakathi kwentsholongwane ye-COVID19 kunye neeseli ezibambayo. Uninzi lwee-antibodies ze-neutralization ziphendula kwi-domain binding domain (RBD) yeprotheni ye-spike, ebophelela ngokuthe ngqo kwi-cell surface receptor ACE2. Amajoni omzimba-kwi-intanethi okwangoku abonelela ngamajoni amabini e-neutralization asekelwe kwi-Clone CR3022. Ngelixa uninzi lwe-S-protein ye-RBD ebopha izilwa-buhlungu zikhuphisana ngokubophelela i-antigen nge-ACE2, i-CR3022 epitope ayidibani nesiza sokubopha i-ACE2.
Ngaloo ndlela ayithinteli ukubophelela kwee-antibodies ze-neutralization. Ngelixa i-CR3022 ngokwayo ibonisa kuphela isiphumo esibuthathaka sokungathathi hlangothi, kubonisiwe ukuba isebenzisana nezinye ii-S-protein RBD ezibophelela izilwa-buhlungu zokulwa i-COVID19.
